Pre-Open Movers 10/18: (GIVN) (SVU) (AEGR) Higher; (ALGN) (MLNX) (IMUC) Lower (more...)
Get Alerts ALGN Hot Sheet
Join SI Premium – FREE
Align Technology, Inc. (NASDAQ: ALGN) 23% LOWER; misses Q3 views, guides Q4 below the Street
CytRx Corporation (Nasdaq: CYTR) 19% LOWER; priced its previously announced underwritten public offering. CytRx is offering 8,000,000 shares of common stock at a public offering price of $2.50.
Mellanox Technologies, Ltd. (NASDAQ: MLNX) 16% LOWER; reported Q3 EPS of $1.37, $0.24 better than the analyst estimate of $1.13. Revenue for the quarter came in at $156.5 million versus the consensus estimate of $153.07 million. Mellanox sees Q4 revenues of $145-$150 million, versus the consensus of $157 million.
ImmunoCellular Therapeutics, Ltd. (NYSE: IMUC) 16% LOWER; intends to offer shares of its common stock and warrants in an underwritten public offering
Gold Resource Corporation (AMEX: GORO) 13% LOWER; Updates on Q3 Production; Lowers FY12 Production Outlook
MannKind Corporation (Nasdaq: MNKD) 13% LOWER; intends to offer and sell, subject to market and other conditions, shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering.
Given Imaging (NASDAQ: GIVN) 12% HIGHER; is currently evaluating a range of strategic options, including preliminary non-binding indications of interest received from a number of parties relating to a possible merger or sale of the Company. The Company intends to continue to actively explore these and other alternatives, including a strategic alliance or additional acquisitions such as the recently announced acquisition of the assets of The Smart Pill Corporation.
SUPERVALU Inc. (NYSE: SVU) 7% HIGHER; received a number of "indications of interest"
Novavax (NASDAQ: NVAX) 7% HIGHER; Achieves Primary Objectives in A/H5N1 Phase 1
Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR) 5% HIGHER; FDA panel backing
MGM Resorts International (NYSE: MGM) 5% HIGHER; Receives Land Lease Approval in Cotai
Clearwire Corporation (NASDAQ: CLWR) 5% HIGHER; Sprint to gain control without a full takeover
BB&T Corp. (NYSE: BBT) 4% LOWER; reported Q3 EPS of $0.70, in-line with the analyst estimate of $0.70. Revenue for the quarter came in at $2.48 billion versus the consensus estimate of $2.46 billion.
Albemarle Corp. (NYSE: ALB) 4% LOWER; reported Q3 EPS of $1.10, $0.02 better than the analyst estimate of $1.08. Revenue for the quarter came in at $662.1 million versus the consensus estimate of $670.18 million.
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) 4% LOWER; commenced an offering to sell shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering.
Philip Morris International, Inc. (NYSE: PM) 3% LOWER; reported Q3 EPS of $1.39, in-line with the analyst estimate of $1.39. Revenue for the quarter came in at $7.9 billion versus the consensus estimate of $8.25 billion. Philip Morris International, Inc. sees FY2012 EPS of $5.12-5.18, versus the consensus of $5.20
ravelers Cos, Inc. (NYSE: TRV) 3% HIGHER; reported Q3 EPS of $2.21, $0.70 better than the analyst estimate of $1.51. Revenue for the quarter came in at $6.51 billion versus the consensus estimate of $5.78 billion
Zillow, Inc. (NYSE: Z) 3% HIGHER; New Buy rating at Goldman Sachs
Biogen Idec Inc. (NASDAQ: BIIB) 3% LOWER; the FDA has extended the initial PDUFA date for its review of the New Drug Application (NDA) for the marketing approval of BG-12 (dimethyl fumarate), the company’s oral therapeutic candidate for the treatment of multiple sclerosis (MS). The 3 month extension is a standard extension period.
Stryker Corp. (NYSE: SYK) 2% LOWER; reported Q3 EPS of $0.97, $0.01 worse than the analyst estimate of $0.98. Revenue for the quarter came in at $2.1 billion versus the consensus estimate of $2.07 billion. Stryker Corp. sees FY2012 EPS of $4.04-4.07, versus prior guidance of $4.25-4.40 and the consensus of $4.09.
Palo Alto Networks, Inc. (NASDAQ: PANW) 2% LOWER; priced 4,800,000 shares of its common stock at $63.00 per share
Xilinx, Inc. (NASDAQ: XLNX) 1% LOWER; reported Q2 EPS of $0.46, $0.05 better than the analyst estimate of $0.41. Revenue for the quarter came in at $543.9 million versus the consensus estimate of $547.74 million. Sees Q3 sales down 1% to down 5% sequentially.
American Express Co. (NYSE: AXP) 1% LOWER; reported Q3 EPS of $1.09, in-line with the analyst estimate of $1.09. Revenue for the quarter came in at $7.9 billion versus the consensus estimate of $7.93 billion.
Lam Research Corp (NASDAQ: LRCX) 1% HIGHER; reported Q1 EPS of $0.53, $0.12 better than the analyst estimate of $0.41. Revenue for the quarter came in at $906.9 million versus the consensus estimate of $903.68 million
Michael Kors Holdings Ltd. (NASDAQ: KORS) 1% HIGHER; new Buy rating at Buckingham
Harley-Davidson, Inc. (NYSE: HOG) 1% HIGHER; upgraded to Buy at Goldman Sachs
CSX Corp. (NYSE: CSX) 1% LOWER; Downgraded at Deustche Bank
Royal Dutch Shell plc (NYSE: RDS-A) 1% LOWER; Downgraded at Goldman Sachs
CytRx Corporation (Nasdaq: CYTR) 19% LOWER; priced its previously announced underwritten public offering. CytRx is offering 8,000,000 shares of common stock at a public offering price of $2.50.
Mellanox Technologies, Ltd. (NASDAQ: MLNX) 16% LOWER; reported Q3 EPS of $1.37, $0.24 better than the analyst estimate of $1.13. Revenue for the quarter came in at $156.5 million versus the consensus estimate of $153.07 million. Mellanox sees Q4 revenues of $145-$150 million, versus the consensus of $157 million.
ImmunoCellular Therapeutics, Ltd. (NYSE: IMUC) 16% LOWER; intends to offer shares of its common stock and warrants in an underwritten public offering
Gold Resource Corporation (AMEX: GORO) 13% LOWER; Updates on Q3 Production; Lowers FY12 Production Outlook
MannKind Corporation (Nasdaq: MNKD) 13% LOWER; intends to offer and sell, subject to market and other conditions, shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering.
Given Imaging (NASDAQ: GIVN) 12% HIGHER; is currently evaluating a range of strategic options, including preliminary non-binding indications of interest received from a number of parties relating to a possible merger or sale of the Company. The Company intends to continue to actively explore these and other alternatives, including a strategic alliance or additional acquisitions such as the recently announced acquisition of the assets of The Smart Pill Corporation.
SUPERVALU Inc. (NYSE: SVU) 7% HIGHER; received a number of "indications of interest"
Novavax (NASDAQ: NVAX) 7% HIGHER; Achieves Primary Objectives in A/H5N1 Phase 1
Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR) 5% HIGHER; FDA panel backing
MGM Resorts International (NYSE: MGM) 5% HIGHER; Receives Land Lease Approval in Cotai
Clearwire Corporation (NASDAQ: CLWR) 5% HIGHER; Sprint to gain control without a full takeover
BB&T Corp. (NYSE: BBT) 4% LOWER; reported Q3 EPS of $0.70, in-line with the analyst estimate of $0.70. Revenue for the quarter came in at $2.48 billion versus the consensus estimate of $2.46 billion.
Albemarle Corp. (NYSE: ALB) 4% LOWER; reported Q3 EPS of $1.10, $0.02 better than the analyst estimate of $1.08. Revenue for the quarter came in at $662.1 million versus the consensus estimate of $670.18 million.
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) 4% LOWER; commenced an offering to sell shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering.
Philip Morris International, Inc. (NYSE: PM) 3% LOWER; reported Q3 EPS of $1.39, in-line with the analyst estimate of $1.39. Revenue for the quarter came in at $7.9 billion versus the consensus estimate of $8.25 billion. Philip Morris International, Inc. sees FY2012 EPS of $5.12-5.18, versus the consensus of $5.20
ravelers Cos, Inc. (NYSE: TRV) 3% HIGHER; reported Q3 EPS of $2.21, $0.70 better than the analyst estimate of $1.51. Revenue for the quarter came in at $6.51 billion versus the consensus estimate of $5.78 billion
Zillow, Inc. (NYSE: Z) 3% HIGHER; New Buy rating at Goldman Sachs
Biogen Idec Inc. (NASDAQ: BIIB) 3% LOWER; the FDA has extended the initial PDUFA date for its review of the New Drug Application (NDA) for the marketing approval of BG-12 (dimethyl fumarate), the company’s oral therapeutic candidate for the treatment of multiple sclerosis (MS). The 3 month extension is a standard extension period.
Stryker Corp. (NYSE: SYK) 2% LOWER; reported Q3 EPS of $0.97, $0.01 worse than the analyst estimate of $0.98. Revenue for the quarter came in at $2.1 billion versus the consensus estimate of $2.07 billion. Stryker Corp. sees FY2012 EPS of $4.04-4.07, versus prior guidance of $4.25-4.40 and the consensus of $4.09.
Palo Alto Networks, Inc. (NASDAQ: PANW) 2% LOWER; priced 4,800,000 shares of its common stock at $63.00 per share
Xilinx, Inc. (NASDAQ: XLNX) 1% LOWER; reported Q2 EPS of $0.46, $0.05 better than the analyst estimate of $0.41. Revenue for the quarter came in at $543.9 million versus the consensus estimate of $547.74 million. Sees Q3 sales down 1% to down 5% sequentially.
American Express Co. (NYSE: AXP) 1% LOWER; reported Q3 EPS of $1.09, in-line with the analyst estimate of $1.09. Revenue for the quarter came in at $7.9 billion versus the consensus estimate of $7.93 billion.
Lam Research Corp (NASDAQ: LRCX) 1% HIGHER; reported Q1 EPS of $0.53, $0.12 better than the analyst estimate of $0.41. Revenue for the quarter came in at $906.9 million versus the consensus estimate of $903.68 million
Michael Kors Holdings Ltd. (NASDAQ: KORS) 1% HIGHER; new Buy rating at Buckingham
Harley-Davidson, Inc. (NYSE: HOG) 1% HIGHER; upgraded to Buy at Goldman Sachs
CSX Corp. (NYSE: CSX) 1% LOWER; Downgraded at Deustche Bank
Royal Dutch Shell plc (NYSE: RDS-A) 1% LOWER; Downgraded at Goldman Sachs
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: RH, Estee Lauder rise; Tesla falls
- Par Pacific (PARR) Announces Expected Term Loan Repricing
- P3 Health Partners Inc. (PIII) Misses Q4 EPS by 14c, reaffirms guidance
Create E-mail Alert Related Categories
Special ReportsRelated Entities
BB&T Capital Markets, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!